CTP-543

Medical professionals may also email us at AAclinicaltrial_inquiries@concertpharma.com for more information about CTP-543 study participation.

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03137381

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT03941548

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT03811912

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Evaluating long-term safety of CTP-543 and to assessing long-term effects of CTP-543 in adult patients with chronic, moderate-to-severe alopecia areata who completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial.

Status: Recruiting
https://clinicaltrials.gov/ct2/show/NCT03898479

CTP-692

Medical professionals may also email us at CNSclinicaltrial_inquiries@concertpharma.com for more information about CTP-692 study participation.

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Assessing in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03880253